Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1996-12-3
|
| pubmed:abstractText |
Recently, Khayat et al. reported that high-dose recombinant interleukin-2 (rIL-2) i.v. may induce tumour regressions in metastatic melanoma patients through an association with cisplatin (CDDP) and alpha-interferon (alpha-IFN). Treatment-related toxicities are, however, important. Previous studies have demonstrated that rIL-2 toxicity may be reduced through a subcutaneous injection. In order to evaluate the effectiveness of low subcutaneous rIL-2 doses in a chemoimmuno-hormonotherapeutic combination, 36 metastatic melanoma patients were treated with CDDP, rIL-2, alpha-IFN and tamoxifen (TAM). The overall response rate was 47.2%: five patients had complete response (14%), 12 partial response (33%) and 13 stable disease (36%). Median response duration was 6.4 months (range: 2-29+). Median overall survival was 10 months (range: 3-36+). The CDDP/rIL-2/alpha-IFN/TAM regimen was effective both on soft tissue and visceral metastases. Toxicity was low and patient management did not require an intensive care unit. A statistically significant increase in both percentage and absolute values of lymphocytes, eosinophils, CD3+/CD4+, CD25+, CD16/56+ and HLA-DR+ cells was found in all patients after two treatment courses. This study shows that lower doses of subcutaneous rIL-2, as well as CDDP and alpha-IFN, associated with TAM, may have similar anticancer efficacy with respect to Khayat's schedule but lower toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0960-8931
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
257-65
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8819129-Adult,
pubmed-meshheading:8819129-Aged,
pubmed-meshheading:8819129-Antineoplastic Agents, Hormonal,
pubmed-meshheading:8819129-Combined Modality Therapy,
pubmed-meshheading:8819129-Disease Progression,
pubmed-meshheading:8819129-Female,
pubmed-meshheading:8819129-Follow-Up Studies,
pubmed-meshheading:8819129-Humans,
pubmed-meshheading:8819129-Interferon-alpha,
pubmed-meshheading:8819129-Interleukin-2,
pubmed-meshheading:8819129-Male,
pubmed-meshheading:8819129-Melanoma,
pubmed-meshheading:8819129-Middle Aged,
pubmed-meshheading:8819129-Neoplasm Metastasis,
pubmed-meshheading:8819129-Neoplasm Staging,
pubmed-meshheading:8819129-Pilot Projects,
pubmed-meshheading:8819129-Recombinant Proteins,
pubmed-meshheading:8819129-Recurrence,
pubmed-meshheading:8819129-Skin Neoplasms,
pubmed-meshheading:8819129-Tamoxifen,
pubmed-meshheading:8819129-Time Factors,
pubmed-meshheading:8819129-Tomography, X-Ray Computed
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma--a pilot study.
|
| pubmed:affiliation |
Clinica Dermatologica dell'Università di Torino, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|